Compare SCCO & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCCO | GILD |
|---|---|---|
| Founded | 1952 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.9B | 184.4B |
| IPO Year | 1996 | 2001 |
| Metric | SCCO | GILD |
|---|---|---|
| Price | $177.16 | $140.11 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | $135.21 | ★ $146.50 |
| AVG Volume (30 Days) | 1.7M | ★ 5.0M |
| Earning Date | 04-24-2026 | 04-23-2026 |
| Dividend Yield | 2.23% | ★ 2.35% |
| EPS Growth | 20.74 | ★ 1684.21 |
| EPS | 5.24 | ★ 6.78 |
| Revenue | $6,654,500,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $16.76 | $4.65 |
| Revenue Next Year | N/A | $5.96 |
| P/E Ratio | $33.94 | ★ $20.61 |
| Revenue Growth | ★ 23.69 | 9.98 |
| 52 Week Low | $74.84 | $95.30 |
| 52 Week High | $223.89 | $157.29 |
| Indicator | SCCO | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 47.28 |
| Support Level | $124.89 | $108.90 |
| Resistance Level | $221.35 | $149.38 |
| Average True Range (ATR) | 7.24 | 3.30 |
| MACD | 2.15 | 0.04 |
| Stochastic Oscillator | 86.25 | 48.48 |
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).